$40MVenture, 17 March 2026
Funds the Phase 1 trial of MST-0312 in solid tumors; total committed capital over $95M.
- Amount
- $40M
- Stage
- Venture
- Announced
- 17 March 2026
- Lead
- SV Health Investors
- Other investors
- Johnson & Johnson Innovation (JJDC), Forbion, GV, Northpond Ventures
- Use of funds
- Funds the Phase 1 trial of MST-0312 in solid tumors; total committed capital over $95M.
- Checked
- Announced by the company
- Sources
- Mestag Therapeutics raises $40M for fibroblast-targeting cancer drugs pharmiweb.com
Mestag Therapeutics raises $40M for fibroblast-targeting cancer drugs finsmes.com